$2.98—Stale · unknown old
XETRA • Last print unknown ago
$2.98—Stale · unknown old
4SC AG is a biotechnology company focused on developing novel therapies for cancer and autoimmune diseases, primarily targeting the European market. Its lead product candidates include 4SC-202 and 4SC-205, which are in various stages of clinical trials, providing a unique position in a competitive landscape dominated by larger pharmaceutical firms.
4SC AG primarily generates revenue through partnerships and collaborations for its clinical trials, leveraging its proprietary drug development platform. The company has a strong pipeline of drug candidates that could provide significant pricing power upon successful commercialization.
Progress in clinical trials for 4SC-202 and 4SC-205
Partnership announcements with larger pharmaceutical companies
Regulatory approvals for drug candidates
Market sentiment towards biotech sector trends
Regulatory changes affecting drug approval processes
Technological disruption in drug development methodologies
Emergence of new therapies from larger competitors
Potential for generic competition if products reach market
High cash burn rate leading to potential liquidity issues
Dependence on external financing for ongoing clinical trials
moderate - The biotechnology sector can be sensitive to economic cycles, as funding for R&D may fluctuate with overall economic conditions.
Higher interest rates could increase the cost of capital for biotech firms like 4SC AG, potentially impacting their ability to finance clinical trials and operations.
minimal - The company has a manageable debt-to-equity ratio of 0.61, indicating limited reliance on credit.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has shown significant price volatility, with a 1-year return of 40.2%.